Caren van Roekel

206 Chapter 7 TABLE S3A . Relation between parenchymal dose (Gy) and cumulative laboratory toxicity over three months, based on linear regression analyses with parenchymal dose as the dependent variable Independent variable Number of patients with toxicity CTCAE grade 0-V Mean change (95% CI); p-value Unadjusted Adjusted for tumor dose, previous treatment and response Any variable, highest grade 37 2.51 (-1.05 – 6.07); 0.16 3.47 (-0.82 – 7.75); 0.11 GGT 25 2.06 (-0.87 – 4.98); 0.16 2.07 (-1.19 – 5.33); 0.20 AP 20 3.64 (0.65 – 6.63); 0.018 3.34 (-0.09 – 6.78); 0.057 Albumin 13 2.75 (-2.07 – 7.56); 0.26 3.20 (-2.26 – 8.66); 0.24 Bilirubin 5 1.98 (-1.71 – 5.66); 0.29 4.98 (0.02 – 9.93); 0.049 ALAT 26 0.48 (-4.44 – 5.41); 0.84 0.84 (-5.58 – 7.27); 0.79 ASAT 30 3.30 (-2.22 – 8.81); 0.23 4.49 (-1.98 – 10.96); 0.17 The mean change indicates the average increase or decrease in parenchymal dose per unit increase in CTCAE grade toxicity. For example, for GGT: a unit increase in toxicity results in an increase in average parenchymal dose of 2.06 Gy (unadjusted analysis). TABLE S3B . Relation between parenchymal dose (Gy) and change in laboratory parameters over three months, based on linear regression analyses with parenchymal dose (per 10 Gy) as the independent variable Dependent variable Mean percent change (95% CI); p-value Unadjusted Adjusted for tumor dose, previous treatment and response ΔGGT 19.6% (-9.1 – 57.3); 0.17 34.1.2% (0.5 – 79.7), 0.043 ΔAP 34.5% (8.5 – 66.7); 0.0063 33.3% (6.5 – 66.6), 0.011 ΔAlbumin -4.1% (-9.7 – 1.8); 0.28 -3.1% (-9.1 – 1.8), 0.71 ΔASAT 18.9% (-4.9 – 48.5); 0.11 14.5% (-9.1 – 44.1), 0.21 ΔALAT 17.3% (-12.7 – 57.7); 0.25 13.3% (-16.5 – 53.6), 0.37 ΔBilirubin 35.1% (-4.5 – 90.7); 0.077 46.6% (3.4 – 107.7), 0.029 The mean change indicates the increase or decrease in average toxicity per 10 Gy increase in parenchymal dose. For example, for GGT: for every 10 Gy increase in parenchymal dose, there is a 19.6% increase in GGT (unadjusted analysis).